Targanta Therapeutics Corporation was a biopharmaceutical company that focused on developing novel antibacterial agents.
The company was founded in 2004.
Targanta Therapeutics Corporation aimed to address the growing problem of antibiotic resistance.
Targanta's lead product candidate was TA-214, an inhaled antibiotic designed to treat respiratory infections.
Acquisitions
Targanta Therapeutics has made a significant acquisition in the field of antibiotics. They acquired the worldwide ownership interest in oritavancin, an antibiotic that has completed two Phase III clinical trials.
Targanta acquired oritavancin from InterMune, Inc. for an upfront cash payment and milestone payments. The acquisition also included the issuance of a convertible promissory note by Targanta, which will initially be secured by the oritavancin assets.
Oritavancin is a semi-synthetic glycopeptide antibiotic with bactericidal activity against clinically relevant serious Gram-positive infections. It has been shown to be an effective and safe therapy for complicated skin and skin structure infections.
The acquisition of oritavancin is a strategic move by Targanta to address the growing need for new antibiotics.
Intriguing read: Class B Shares Private Company
Corporate Structure
Targanta Therapeutics Corporation has a corporate structure that includes a board of directors and several key executives.
The company was founded in 2004 by a team of experienced pharmaceutical professionals, including Dr. Steven C. Gilman, who served as the company's President and CEO.
The board of directors oversees the company's overall strategy and direction, with members including Dr. Steven C. Gilman and other industry experts.
Targanta's corporate structure is designed to support the company's mission of developing innovative treatments for infectious diseases.
The company's leadership team includes Dr. Steven C. Gilman, President and CEO, and Dr. Robert J. Spiegel, Chief Medical Officer.
For another approach, see: Target Corp Organizational Structure
Acquisition Details
Targanta Therapeutics's acquisition details are a significant part of its history. The company was acquired, but the exact date of the acquisition is not specified.
One notable fact about Targanta Therapeutics is that it was ranked 61st in the list of companies, with a Tracxn Score of 41/100. This score indicates that the company's overall performance and growth potential are relatively lower compared to the other companies in the list.
See what others are reading: List of Largest Pharmaceutical Mergers and Acquisitions
Targanta Therapeutics received a total of $70M in funding from investors such as Skyline Ventures, Brookside Capital, and 5 others. This funding was a crucial part of the company's development and growth.
Here's a list of the top 5 companies in the list, which includes Spero Therapeutics, Nabriva, Iterum Therapeutics, Melinta Therapeutics, and Cubist Pharmaceuticals, ranked by their total funding:
It's worth noting that Cubist Pharmaceuticals' total funding is not specified, but it's ranked 5th in the list.
Featured Images: pexels.com
